Costs and outcomes of colorectal cancer screening program in Isfahan, Iran.
Colorectal cancer
Direct costs
Outcomes
Screening
Journal
BMC health services research
ISSN: 1472-6963
Titre abrégé: BMC Health Serv Res
Pays: England
ID NLM: 101088677
Informations de publication
Date de publication:
05 Jan 2023
05 Jan 2023
Historique:
received:
22
02
2022
accepted:
26
12
2022
entrez:
5
1
2023
pubmed:
6
1
2023
medline:
10
1
2023
Statut:
epublish
Résumé
Colorectal cancer is one of the most prevalent gastrointestinal cancers in Iran i.e., the fourth and the second prevalent cancer among Iranian males and females, respectively. A routine screening program is effective in the early detection of disease which can reduce the cancer burden both for individuals and society. In 2015, Iran's Package of Essential Non- communicable Diseases program had been piloted in Shahreza city in Isfahan province. Colorectal cancer screening for the population aged 50-70 was a part of this program. So far, there was no study about the cost and outcomes of that program. Thus, this study aimed to analyze the costs and outcomes of colorectal cancer screening done from 2016 to 2019 in Shahreza. This cost-outcome description study used the data of 19,392 individuals who were 50-70 years old experienced a fecal immunochemical test (FIT) and had an electronic health record. All direct costs including personnel, building space, equipment, training, etc. were extracted from the financial documents existing in the Isfahan province Health Center. The outcome was defined as positive FIT, detection of adenoma or malignancy as recorded in the E-integrated health system. The results of this study indicated that the direct costs of the colorectal cancer screening program during the years 2016-2019 were 7,368,707,574 Rials (321,029 PPP$) in Shahreza, Isfahan province. These costs resulted in identifying 821 people with a positive FIT test, of those 367 individuals were undergone colonoscopy. Of whom 8 cases of colorectal cancer, and 151 cases with polyps were diagnosed. This study showed that by paying a small amount of 320 thousand international dollars we could prevent 151 cases of polyps to be progressed to colorectal cancer,resulting in a significant reduction in colorectal cancer incidence.
Sections du résumé
BACKGROUND
BACKGROUND
Colorectal cancer is one of the most prevalent gastrointestinal cancers in Iran i.e., the fourth and the second prevalent cancer among Iranian males and females, respectively. A routine screening program is effective in the early detection of disease which can reduce the cancer burden both for individuals and society. In 2015, Iran's Package of Essential Non- communicable Diseases program had been piloted in Shahreza city in Isfahan province. Colorectal cancer screening for the population aged 50-70 was a part of this program. So far, there was no study about the cost and outcomes of that program. Thus, this study aimed to analyze the costs and outcomes of colorectal cancer screening done from 2016 to 2019 in Shahreza.
METHODS
METHODS
This cost-outcome description study used the data of 19,392 individuals who were 50-70 years old experienced a fecal immunochemical test (FIT) and had an electronic health record. All direct costs including personnel, building space, equipment, training, etc. were extracted from the financial documents existing in the Isfahan province Health Center. The outcome was defined as positive FIT, detection of adenoma or malignancy as recorded in the E-integrated health system.
RESULTS
RESULTS
The results of this study indicated that the direct costs of the colorectal cancer screening program during the years 2016-2019 were 7,368,707,574 Rials (321,029 PPP$) in Shahreza, Isfahan province. These costs resulted in identifying 821 people with a positive FIT test, of those 367 individuals were undergone colonoscopy. Of whom 8 cases of colorectal cancer, and 151 cases with polyps were diagnosed.
CONCLUSION
CONCLUSIONS
This study showed that by paying a small amount of 320 thousand international dollars we could prevent 151 cases of polyps to be progressed to colorectal cancer,resulting in a significant reduction in colorectal cancer incidence.
Identifiants
pubmed: 36604670
doi: 10.1186/s12913-022-09010-1
pii: 10.1186/s12913-022-09010-1
pmc: PMC9817386
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
13Informations de copyright
© 2023. The Author(s).
Références
BMC Cancer. 2018 Apr 25;18(1):464
pubmed: 29695234
Clin Gastroenterol Hepatol. 2018 Apr;16(4):504-512.e11
pubmed: 28733262
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Fam Pract. 2020 Jul 23;37(3):321-324
pubmed: 31961429
Value Health. 2017 Jun;20(6):809-818
pubmed: 28577699
Cancer Med. 2018 Sep;7(9):4781-4790
pubmed: 30101513
PLoS One. 2021 Jan 12;16(1):e0243587
pubmed: 33434195
World J Gastrointest Pathophysiol. 2017 Feb 15;8(1):3-10
pubmed: 28251034
J Med Screen. 2021 Sep;28(3):268-276
pubmed: 33153369
Asian Pac J Cancer Prev. ;18(10):2883-2889
pubmed: 29072830
Ecancermedicalscience. 2021 Sep 13;15:1285
pubmed: 34824608
Lancet Public Health. 2017 Jul;2(7):e331-e340
pubmed: 29253458
Arch Iran Med. 2017 Dec 01;20(12):726-733
pubmed: 29664311
Cancer. 2018 Nov 1;124(21):4121-4129
pubmed: 30359468
Eur J Cancer Prev. 2006 Oct;15(5):384-90
pubmed: 16912566
Ann Gastroenterol. 2017;30(4):442-445
pubmed: 28655982
Eval Program Plann. 2017 Jun;62:67-72
pubmed: 27989647
Arch Iran Med. 2011 Mar;14(2):110-4
pubmed: 21361717